Cancer Immunotherapy: The Newest Weapon to Fight Cancer
Over the past few years, cancer immunotherapy has become an integral part of the treatment of certain types of cancer. Immunotherapy involves the use of certain parts of a patient’s immune system to treat the disease.
This treatment works in different ways:
Request a Sample Copy of This Report: https://www.radiantinsights.com/research/global-cancer-immunotherapy-market-size-status-and-forecast-2022/request-sample
New Immunotherapy Combinations for Lung Cancer Treatment
Growing cases of lung cancer across the globe contribute toward rising adoption of cancer immunotherapy. Various organizations are focused on developing novel lung cancer treatments.
At present, the checkpoint inhibitors Keytruda, Tecentriq, and Opdivo (nivolumab) have been approved for the second-line treatment of non-small cell lung cancer (NSCLC). Among these, Keytruda is an FDA-approved drug even in frontline settings. According to one of the experts, tremelimumab—a fully human monoclonal antibody against Cytotoxic T Lymphocyte–Associated Antigen 4 (CTLA-4)—and Imfinzi as a combination is a major area, as it includes an anti–CTLA-4 agent, as well as an anti–PD-L1 agent. Combination of these two agents can show a lot of promise in the field of NSCLC treatment.
Experts are further looking at several other combinations of immunotherapy agents to improve patient response rates. Researchers in the field of lung cancer treatment are hoping that the new agents and combinations will continue to improve the field over the coming years.
Market Insights
Based on the findings of a new research available on Radiant Insights, Inc.; the worldwide cancer immunotherapy market is expected to have a robust growth rate over the forecast period (from 2017 to 2021). Ever increasing cases of cancer along with the adoption of latest therapeutics are said to propel the market growth over the next few years. In addition, constant introduction of new drugs is also anticipated to further support the development in near future.
The market for cancer immunotherapy is highly competitive and some major companies in this market include F. Hoffmann-La Roche AG; Pfizer, Inc.; Bristol-Myers Squibb Co.; Eli Lilly and Co.; Merck and Co., Inc.; and Novartis AG.
Browse Full Research Report With TOC: https://www.radiantinsights.com/research/global-cancer-immunotherapy-market-size-status-and-forecast-2022
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Details: https://www.radiantinsights.com
This treatment works in different ways:
- Stimulating immune system to effectively attack cancer cells
- Giving immune system components like artificial immune system proteins
Request a Sample Copy of This Report: https://www.radiantinsights.com/research/global-cancer-immunotherapy-market-size-status-and-forecast-2022/request-sample
New Immunotherapy Combinations for Lung Cancer Treatment
Growing cases of lung cancer across the globe contribute toward rising adoption of cancer immunotherapy. Various organizations are focused on developing novel lung cancer treatments.
At present, the checkpoint inhibitors Keytruda, Tecentriq, and Opdivo (nivolumab) have been approved for the second-line treatment of non-small cell lung cancer (NSCLC). Among these, Keytruda is an FDA-approved drug even in frontline settings. According to one of the experts, tremelimumab—a fully human monoclonal antibody against Cytotoxic T Lymphocyte–Associated Antigen 4 (CTLA-4)—and Imfinzi as a combination is a major area, as it includes an anti–CTLA-4 agent, as well as an anti–PD-L1 agent. Combination of these two agents can show a lot of promise in the field of NSCLC treatment.
Experts are further looking at several other combinations of immunotherapy agents to improve patient response rates. Researchers in the field of lung cancer treatment are hoping that the new agents and combinations will continue to improve the field over the coming years.
Market Insights
Based on the findings of a new research available on Radiant Insights, Inc.; the worldwide cancer immunotherapy market is expected to have a robust growth rate over the forecast period (from 2017 to 2021). Ever increasing cases of cancer along with the adoption of latest therapeutics are said to propel the market growth over the next few years. In addition, constant introduction of new drugs is also anticipated to further support the development in near future.
The market for cancer immunotherapy is highly competitive and some major companies in this market include F. Hoffmann-La Roche AG; Pfizer, Inc.; Bristol-Myers Squibb Co.; Eli Lilly and Co.; Merck and Co., Inc.; and Novartis AG.
Browse Full Research Report With TOC: https://www.radiantinsights.com/research/global-cancer-immunotherapy-market-size-status-and-forecast-2022
About Radiant Insights,Inc
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Details: https://www.radiantinsights.com
Comments
Post a Comment